NCT02469688View on ClinicalTrials.gov

A Study of ASP4070 to Confirm Safety and Immunological Response in Patients With Pollen Allergy

PHASE1CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

June 18, 2015

Primary Completion Date

November 27, 2015

Study Completion Date

July 26, 2016

Conditions
Cedar Pollinosis
Interventions
DRUG

ASP4070

intramuscular or intradermal

DRUG

Placebo

intramuscular or intradermal

Trial Locations (1)

Unknown

Kanto

Sponsors
All Listed Sponsors
collaborator

Immunomic Therapeutics, Inc.

INDUSTRY

lead

Astellas Pharma Inc

INDUSTRY